# Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

> **NCT01130753** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 43 (estimated)

## Conditions studied

- Lung Neoplasms
- Erlotinib
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01130753
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-12
- **Final completion:** 2012-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130753, "Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01130753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*